蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1892|回复: 8
收起左侧

India issues Guidelines for Certification of API Exports to EU

[复制链接]
药徒
发表于 2013-4-4 12:42:02 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x

  
India issues Guidelines for Certification of API Exports to EU - can the EU accept this Certification?

After the announcement from India that the Central Drugs Standards Control Organization (CDSCO) would be the competent authority to issue written confirmations as required by the Falsified Medicines Directive for importing APIs into the European Union, all eyes were on the Indian Regulator to announce the procedure for issuance of such certification. The Indian regulator has now published documents on its website. These documents give administrative procedure to be followed by manufacturers and the CDSCO. However it is surprising that both the Indian "Drugs and Cosmetics Act" and the Indian "Drugs and Cosmetics Rules" do not have any provision for issuance of a guidance document. But these documents have been published as guidelines and SOPs. So some questions might be asked: how do these documents become a statute or a regulation or a standard? And are they an enforcement tool or do they have any legislative sanction and legal status? The standard for GMPs has remained unchanged and this standard is not equivalent to ICH Q7 or Part 2 of the EU-GMP Guide. India has a federal structure with each state having its own local Food and Drugs administration who issue the manufacturing license for the manufacture of an API. The inspectors of these local offices have the legal authority to inspect the manufacturing premises and not the CDSCO, which is a Central Authority. So now there is a somehow paradox situation where the standards for GMP are national Indian Standards enforced by the state/provincial Indian FDA and there is a Written Confirmation issued by CDSCO as a central agency with no enforcement authority and no oversight of GMP implementation. Uday Shetty points out that India first needs to have a Regulatory Standard in place which is equivalent to the EU standard and than have an effective enforcement practice in place. Once this is realised, a Written Confirmation can be issued. He thinks that Written Confirmations can not be given until GMP standards and enforcement are really equivalent to those in the EU. For this India needs to change its statutes, modify the GMP regulations in the Indian Drugs and Cosmetics Act and rules to incorporate the GMP requirements of ICH Q7 and introduce regulatory and/or legislative measures for effective  enforcement of GMPs before a legally valid certification required by EU Directive can be issued.
回复

使用道具 举报

药生
发表于 2013-4-4 13:56:15 | 显示全部楼层
印度问题的API出口欧盟认证指南可以欧盟接受此证书吗?
回复

使用道具 举报

药生
发表于 2013-4-4 13:56:55 | 显示全部楼层
印度宣布,中央药品标准控制组织(卫生部下设)将发出书面确认所伪造的药品进口原料药的指令为欧盟主管机关,所有的眼睛都在印度监管机构宣布发行等认证程序。印度监管机构已在其网站上公布的文件。这些文件给行政程序应遵循的制造商和卫生部下设。然而令人惊讶的是,印度药品和化妆品法案》和印度药品和化妆品的规则”,没有一个指导性文件发行的任何规定。但这些文件已公布的指导方针和标准操作规程。因此有些问题可能会问:如何将这些文件成为一个法律或法规或标准?和他们的执法工具或他们有法律制裁和法律地位?对于GMP标准保持不变,这个标准是不等价的EU-GMP引导部分ICH Q7或2。印度有一个联邦结构的每个国家有它自己的本地食品和药物管理局颁发的API生产制造许可证。这些当地办事处的人员有权检查制造场所及不卫生部下设的,这是一个中央的权威。所以现在有一种莫名其妙的悖论在GMP标准是国家印度标准/省印度FDA并有书面确认的卫生部下设作为一个没有执法机构和无监督实施GMP的中央机构执行的状态。乌代Shetty指出印度首先需要有一个监管标准到位,这相当于欧盟的标准,比有一个有效的执法实践。这是一次意识到,可发出书面确认。他认为书面确认不能考虑到GMP标准和执行是相当于欧盟。为此印度需要改变它的法规,修改在印度药品和化妆品法案和规则的GMP法规将ICH Q7 GMP要求,并介绍GMP的有效实施监管和/或立法措施在合法有效的认证由欧盟指令要求可以发出。
回复

使用道具 举报

药生
发表于 2013-4-4 13:58:12 | 显示全部楼层
俺英语不好,用百度翻译的。要不容易当成广告处理的。
回复

使用道具 举报

药生
发表于 2013-4-4 14:00:28 | 显示全部楼层
这个也没怎么关注过。
回复

使用道具 举报

发表于 2013-4-30 17:17:32 | 显示全部楼层
我反复看了多遍,好帖,得支持












faguo.wungklom.comfaguo.wungklom.com
回复

使用道具 举报

发表于 2013-5-26 16:43:55 | 显示全部楼层
好帖,有才!用一句话概况:西医西药是救命的,中医中药是治病的。
详情中医咨二二二六九九一五零二.












益腺康采用纯中药辨证论治,针对患者具体病症用药治疗。单人单方,治愈后注意饮食作息,保持良好的生活方式。疏肝散结,清热利湿。药食同源,药效专一,疗效确切。QQ2226991502
回复

使用道具 举报

药徒
发表于 2013-7-3 20:55:40 | 显示全部楼层
这是什么东西
回复

使用道具 举报

发表于 2013-7-6 23:21:53 | 显示全部楼层
回帖是必须的,这个可以有!
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-6-5 19:57

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表